Background Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection (LRTI) hospitalization in infants globally. While nirsevimab has shown effectiveness in typical 5–6 month seasons, evidence during prolonged seasons and under surveillance-guided immunization strategies is limited.Methods In this population-based retrospective cohort study in Beijing, China, 114,572 infants born between April 1, 2025, and March 31, 2026, were followed through a 9-month RSV season defined by real-time surveillance. A single dose of nirsevimab was administered via a voluntary, self-pay programme under the surveillance-guided strategy. Outcomes included RSV‑associated LRTI hospitalisation (primary), severe RSV‑associated LRTI (ICU admission or mechanical ventilation), and all‑cause LRTI hospitalisation (secondary). Effectiveness was estimated as (1 – adjusted incidence rate ratio) × 100% using Poisson regression, adjusting for birth cohort, age, sex, gestational age, birth weight, and receipt of self-paid vaccines. Pre-specified subgroup analyses were performed across the risk spectrum—including preterm and low-birthweight infants—by sex, age, birth cohort, gestational age, and birth weight, with interaction tests.Findings Of 114,572 eligible infants (87.8% aged ≤3 months; 51.8% male), 8,976 (7.8%) received nirsevimab. RSV-associated LRTI hospitalization occurred in 23 recipients (5.2 per 1,000 person-years) and 1,229 non-recipients (21.0 per 1,000 person-years), yielding 77.7% effectiveness (95% CI, 66.2–85.3; P < .001) and an absolute rate difference of 15.8 per 1,000 person-years. Effectiveness was 85.8% (95% CI, 42.1–96.5; P = .006) against severe RSV-associated LRTI and 39.0% (95% CI, 26.4–49.5; P < .001) against all-cause LRTI hospitalization. Protection was consistent across gestational age and birth weight subgroups despite substantially higher baseline rates in preterm and low-birthweight infants. Effectiveness varied by birth cohort (89.7% in catch-up vs 66.4% in seasonal; P for interaction = .010). Results were robust in sensitivity analyses.Interpretation During a prolonged season, nirsevimab provided substantial and durable protection against RSV-associated hospitalization under a surveillance-guided programme, supporting data-driven immunization timing in settings with unpredictable seasonality.Funding Capital's Funds for Health Improvement and Research (2026-1G-3012).